



Press Release

Cilian Provides Update on Vaccine Program

Münster, Germany, July 2016:

Cilian has completed a number of *in vivo* efficacy studies on its sub-unit seasonal flu vaccine for human use. Studies in mice and primates have consistently shown marked efficacy at values better than currently used egg-based vaccines.

In addition, Cilian has demonstrated its ability to develop its vaccine for veterinary applications, particularly against pandemic influenza strains of porcine origin; and against non-enveloped viruses in porcine populations. Both approaches were tested *in vivo* and have shown convincing immunogenicity.

Cilian is also pursuing the development of two other applications based on its own sub-unit seasonal flu vaccine for human use through collaborations: a nano-particle flu vaccine; and a solid implant vaccine.

About Cilian Flu Vaccine Program

Through its proprietary protein expression technology (CIPEX®), Cilian has developed and tested sub-unit vaccines directed towards protection of humans from seasonal influenza. These vaccines have consistently shown to be efficacious *in vivo* without the use of adjuvants. Production time is significantly shorter than for egg-based flu vaccines; contamination issues can be eliminated; and production costs have been calculated to be significantly reduced. Cilian has also generated positive *in vivo* data for veterinary applications.

About Cilian

Cilian AG, founded in 2001 by Dr. Marcus Hartmann, is a biotech company developing and marketing a new expression system. It uses eukaryotic single cell microorganisms called Ciliates for the production of therapeutic antibodies, vaccines and enzymes. Cilian applies this platform for the development of its own subunit vaccine for seasonal influenza and a lipase based enzyme preparation to treat exocrine pancreatic insufficiency.

Additional information can be found at www.cilian.com

Cilian AG:

Marcus Hartmann, Ph.D. (CSO)

tel. +49 251 6 20 31 0

hartmann@cilian.de